Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) – Research analysts at B. Riley issued their FY2017 EPS estimates for shares of Adamis Pharmaceuticals Corporation in a report released on Wednesday. B. Riley analyst A. D’silva anticipates that the specialty pharmaceutical company will post earnings of ($0.78) per share for the year. B. Riley currently has a “Buy” rating and a $10.00 target price on the stock. B. Riley also issued estimates for Adamis Pharmaceuticals Corporation’s Q4 2017 earnings at ($0.14) EPS, Q1 2018 earnings at ($0.14) EPS, Q2 2018 earnings at ($0.13) EPS, Q3 2018 earnings at ($0.17) EPS, Q4 2018 earnings at ($0.16) EPS, FY2018 earnings at ($0.60) EPS, FY2019 earnings at ($0.56) EPS, FY2020 earnings at ($0.50) EPS and FY2021 earnings at ($0.37) EPS.

COPYRIGHT VIOLATION WARNING: “B. Riley Weighs in on Adamis Pharmaceuticals Corporation’s FY2017 Earnings (ADMP)” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/18/b-riley-weighs-in-on-adamis-pharmaceuticals-corporations-fy2017-earnings-admp.html.

Other equities analysts have also issued research reports about the stock. Raymond James Financial, Inc. began coverage on shares of Adamis Pharmaceuticals Corporation in a research report on Tuesday, September 12th. They set an “outperform” rating and a $7.00 target price on the stock. Maxim Group reaffirmed a “buy” rating and set a $13.00 target price on shares of Adamis Pharmaceuticals Corporation in a research report on Monday, August 21st. Finally, ValuEngine lowered shares of Adamis Pharmaceuticals Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) opened at $4.20 on Friday. Adamis Pharmaceuticals Corporation has a 52-week low of $2.55 and a 52-week high of $6.45. The company has a quick ratio of 2.04, a current ratio of 2.19 and a debt-to-equity ratio of 0.08.

A number of institutional investors have recently made changes to their positions in ADMP. First Allied Advisory Services Inc. bought a new stake in Adamis Pharmaceuticals Corporation in the 2nd quarter valued at $114,000. Bank of New York Mellon Corp increased its holdings in Adamis Pharmaceuticals Corporation by 131.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock valued at $143,000 after buying an additional 15,577 shares during the period. Stonebridge Capital Advisors LLC increased its holdings in Adamis Pharmaceuticals Corporation by 22.2% in the 2nd quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock valued at $143,000 after buying an additional 5,000 shares during the period. Wells Fargo & Company MN bought a new stake in Adamis Pharmaceuticals Corporation in the 2nd quarter valued at $169,000. Finally, IFP Advisors Inc increased its holdings in Adamis Pharmaceuticals Corporation by 2,245.6% in the 2nd quarter. IFP Advisors Inc now owns 34,433 shares of the specialty pharmaceutical company’s stock valued at $179,000 after buying an additional 32,965 shares during the period. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Earnings History and Estimates for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.